Table 1 Patient characteristics for colesevelam HCL users
From: Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
Characteristic | All T2DM patients (N = 1747) |
|---|---|
Age (n, %) | |
18-44 years | 132 (7.56%) |
45-49 years | 149 (8.53%) |
50-54 years | 208 (11.91%) |
55-59 years | 299 (17.12%) |
60-64 years | 300 (17.17%) |
65-69 years | 263 (15.05%) |
70-74 years | 195 (11.16%) |
75-79 years | 126 (7.21%) |
≥ 80 years | 75 (4.29%) |
Sex (n, %) | |
Female | 1018 (58.27%) |
Male | 729 (41.73%) |
Race (n, %) | |
White | 938 (53.69%) |
Black | 160 (9.16%) |
Asian | 6 (0.34%) |
Other | 47 (2.69%) |
Unknown | 596 (34.12%) |
Insurance Type (n, %) | |
Commercial | 454 (25.99%) |
Medicare | 637 (36.46%) |
Medicaid | 24 (1.37%) |
Self-Pay | 10 (0.57%) |
Other | 8 (0.46%) |
Unknown | 614 (35.15%) |
Region (n, %) | |
Midwest | 350 (20.03%) |
Northeast | 433 (24.79%) |
South | 847 (48.48%) |
West | 117 (6.70%) |
Baseline A1c Values (mean, SD) | 8.25 (1.32) |
Prior T2DM Treatments (n, %) | |
Biguanide | 266 (15.23%) |
Insulin | 506 (28.96%) |
Sulfonylurea | 231 (13.22%) |
Thiazolidinediones | 118 (6.75%) |
DPP-4 inhibitor | 63 (3.61%) |
Other Miscellaneous | 64 (3.66%) |
Number of Prior T2DM Treatments (n, %) | |
0 | 808 (46.25%) |
1 | 687 (39.32%) |
2 | 204 (11.68%) |
3 | 42 (2.40%) |
≥4 | 6 (0.34%) |